Charles Schwab Investment Management Inc. boosted its stake in shares of Relx Plc (NYSE:RELX - Free Report) by 19.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 143,483 shares of the technology company's stock after acquiring an additional 23,183 shares during the period. Charles Schwab Investment Management Inc.'s holdings in Relx were worth $6,517,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Private Trust Co. NA lifted its stake in Relx by 19.2% in the fourth quarter. Private Trust Co. NA now owns 1,237 shares of the technology company's stock worth $56,000 after acquiring an additional 199 shares during the period. Peapack Gladstone Financial Corp lifted its holdings in shares of Relx by 5.7% during the third quarter. Peapack Gladstone Financial Corp now owns 4,924 shares of the technology company's stock worth $234,000 after purchasing an additional 267 shares during the period. EWA LLC lifted its holdings in shares of Relx by 5.2% in the 3rd quarter. EWA LLC now owns 5,501 shares of the technology company's stock valued at $253,000 after buying an additional 272 shares during the period. Marks Group Wealth Management Inc grew its position in shares of Relx by 1.3% during the 4th quarter. Marks Group Wealth Management Inc now owns 26,196 shares of the technology company's stock valued at $1,190,000 after acquiring an additional 325 shares during the period. Finally, Raymond James Trust N.A. raised its position in Relx by 2.6% during the third quarter. Raymond James Trust N.A. now owns 15,631 shares of the technology company's stock worth $742,000 after acquiring an additional 399 shares during the period. 15.02% of the stock is owned by institutional investors.
Relx Trading Up 0.3 %
NYSE:RELX traded up $0.14 during trading hours on Friday, reaching $50.21. 560,996 shares of the company were exchanged, compared to its average volume of 757,693. The firm has a market cap of $93.18 billion, a price-to-earnings ratio of 26.99, a PEG ratio of 2.73 and a beta of 0.90. The company has a debt-to-equity ratio of 1.46, a current ratio of 0.52 and a quick ratio of 0.47. The stock has a 50 day simple moving average of $49.44 and a 200 day simple moving average of $47.80. Relx Plc has a 52-week low of $40.25 and a 52-week high of $51.99.
Relx Increases Dividend
The company also recently declared a semi-annual dividend, which will be paid on Wednesday, June 25th. Investors of record on Friday, May 9th will be issued a dividend of $0.5586 per share. This represents a yield of 1.6%. This is a positive change from Relx's previous semi-annual dividend of $0.23. The ex-dividend date of this dividend is Friday, May 9th. Relx's dividend payout ratio (DPR) is presently 59.68%.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on RELX shares. Barclays raised shares of Relx from an "equal weight" rating to an "overweight" rating in a research note on Friday, March 14th. The Goldman Sachs Group initiated coverage on shares of Relx in a research note on Wednesday. They issued a "buy" rating for the company. StockNews.com downgraded shares of Relx from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Finally, Redburn Atlantic assumed coverage on Relx in a research note on Wednesday, January 8th. They set a "buy" rating for the company. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Relx currently has an average rating of "Buy".
Check Out Our Latest Report on Relx
About Relx
(
Free Report)
RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.
See Also
Before you consider Relx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relx wasn't on the list.
While Relx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
